DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Low Molecular Weight Heparin in Recurrent Implantation Failure

Information source: V.K.V. American Hospital, Istanbul
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infertility; Fertilization in Vitro; Recurrent Implantation Failure

Intervention: low molecular weight heparin (enoxaparine sodium) (Drug); crinone 8% gel (Drug)

Phase: N/A

Status: Completed

Sponsored by: V.K.V. American Hospital, Istanbul

Official(s) and/or principal investigator(s):
Cumhur B Urman, M.D., Study Director, Affiliation: American Hospital of Istanbul

Summary

Recurrent implantation failure is the failure to achieve a pregnancy after multiple attempts with in vitro fertilization treatment. The reason is usually obscure. Many empirical treatments have been offered without substantial evaluation. Heparin is thought to play a role in the embryo implantation process beyond its anticoagulation effects. The proposed study aims to assess the effectiveness and safety of empirical administration of low molecular weight heparin in patients undergoing a new IVF treatment cycle after multiple failed attempts.

Clinical Details

Official title: Empirical Low Molecular Weight Heparin Administration in the Luteal Phase in Patients With Recurrent Implantation Failures: a Randomized Open Labeled Trial

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Ongoing pregnancy beyond the 20th gestational week rate

Secondary outcome:

Clinical pregnancy rate

Embryo implantation rate

Eligibility

Minimum age: 18 Years. Maximum age: 38 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- History of at least two previously failed fresh embryo transfer cycles

- All previously failed cycles to be performed in the American Hospital of Istanbul

- Female age ≤ 38 years

- Fresh ejaculate sperms to be used for ICSI

- No hormonal, coagulation, or immunological disorders detected

- Normal uterine cavity, as assessed by diagnostic office hysteroscopy or saline

infusion sonography

- Normal female and male peripheral karyotype

Locations and Contacts

Assisted Reproduction Unit of the American Hospital of Istanbul, Istanbul 34365, Turkey
Additional Information

Starting date: January 2006
Last updated: March 19, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017